HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

Phase 4

Completed

• Conditions: HIV
• Interventions: Drug: Observational

• Registration Number: NCT01808352
• Lead Sponsor: HIV Prevention Trials Network

Brief Summary

Black men who have sex with men (MSM) Pre-Exposure Prophylaxis (PrEP) Study with Client Centered Care Coordination (C4) Component.

Detailed Description

An open label demonstration study with PrEP and Client Centered Care Coordination (C4) to assess the initiation, acceptability, safety, and feasibility of PrEP for Black MSM (BMSM) in three US Cities. A subset of participants will also be recruited to participate in qualitative interviews about facilitators and barriers regarding PrEP. The study will recruit HIV-uninfected BMSM at risk for HIV infection in three US Cities. Enrollment will include those aged 18 and over with an effort to recruit an equal number of BMSM under age 25 and over age 25 with a total of 225 participants (75 per site).

Study Timeline

• Study First Submitted: 2013-03-05
• Study First Submitted QC: 2013-03-07
• Study First Posted: 2013-03-11
• Study Start: 2013-08-15
• Primary Completion: 2015-09-30
• Study Completion: 2015-09-30
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-02
• Last Update Posted: 2025-05-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 226

Inclusion Criteria

BMSM who meet all of the following criteria are eligible for inclusion in this study:

• 18 years of age or older

• No prior HIV diagnosis (self-report)

• Male at birth

• High risk for acquiring HIV infection including any one of the following in the previous 6 months:

  • Unprotected sex during receptive or insertive anal intercourse with a male partner

  • Any protected or unprotected:

    i. Receptive or insertive anal intercourse with more than three male sex partners ii. Exchange of money, gifts, shelter or drugs for receptive or insertive anal sex with a male partner iii. Receptive or insertive anal sex while under the influence of drugs or alcohol (i.e., high or drunk within two hours of the sex act) according to self-report"

  • STI diagnosis (i.e., syphilis, gonorrhea and chlamydia) by self-report

• Willing to provide locator information in accordance with the Study Specific Procedures (SSP) Manual

• Urine dipstick negative or trace for protein and glucose

• Hemoglobin > 11 g/dL, absolute neutrophil count > 750 cells/mm3, and platelet count ≥ 100,000/mm3

• Serum creatinine < upper limit of normal (ULN) and calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault formula where:

  o eCcr in mL/min = [(140 - age in years) x (actual body weight in kg)] / (72 x serum creatinine in mg/dL) Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) < 3 times the upper limit of normal (ULN)

• Total bilirubin < 2.5 ULN

• Hepatitis B surface antigen (HBsAg) negative

Exclusion Criteria

BMSM who meet any of the following criteria will be excluded from this study:

• Any reactive or positive HIV test at Screening, even if subsequent testing indicates that the person is HIV-uninfected
• Transgender
• Active or chronic hepatitis B infection (as evidenced by HBsAg, HbsAb, and HbcAb testing)
• Planning to move out of the area or to travel for more than 3 months during the study follow-up period
• Unwilling to adhere to study procedures
• Current participation in any research study via self-report (however, strictly non-HIV centered observational studies are not exclusionary)
• Previous participation in an HIV vaccine study is exclusionary unless documented evidence of enrollment into a placebo arm
• Use of ARV drugs (PrEP or PEP) in the last 60 days
• Prior history of a gastrectomy, colostomy, ileostomy, or any other procedure altering the gastrointestinal tract or drug absorption (provided by self-report, or obtained from medical history or records)
• Receipt of prohibited medications: interleukin therapy, medications with significant nephrotoxic potential (including but not limited to amphotericin B, aminoglycosides, cidofovir, foscarnet and systemic chemotherapy), and medications that may inhibit or compete for elimination via active renal tubular secretion (including but not limited to probenecid) - (provided by self-report, or obtained from medical history or medical records)
• Any condition, that in the opinion of study staff, would make participation in the study unsafe, or interfere with achieving the study objective

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Observational	Observational	Observational study

Primary Outcome Measures

Name	Time	Method
Initiation of PrEP	30 months	Documented in either study CRFs or ACASI
Adherence to PrEP	30 months	Adherence will be assessed via self-report (ACASI), PBMCs and plasma concentration

Secondary Outcome Measures

Name	Time	Method
STIs	30 months	Rectal and urine GC/CT, and NAAT for syphilis and chlamydia
Adverse events	30 months	Graded via DAIDS Toxicity Grading System determined by review of reported adverse events (clinical and laboratory)
Incident HIV-seroconversions/characteristics	30 months	HIV RNA and genotyping will be performed at the NL on samples confirmed to be HIV infected
Changes in sexual risk-taking behavior	30 months	Measured by ACASI assessments
Initiate or decline PrEP	30 months	Refusal rates will be measured by ACASI assessments
Participant perception of care and referral plan	30 months	Assessed via interviewer-administered questionnaire

Trial Locations

Locations (3)

George Washington University CRS; 🇺🇸 Washington, District of Columbia, United States

UCLA Vine Street Clinic; 🇺🇸 Los Angeles, California, United States

UNC CRS; 🇺🇸 Chapel Hill, North Carolina, United States